These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21839579)

  • 1. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
    Niegisch G; Fimmers R; Siener R; Park SI; Albers P;
    Eur Urol; 2011 Nov; 60(5):1087-96. PubMed ID: 21839579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
    Palacka P; Mego M; Obertova J; Chovanec M; Sycova-Mila Z; Mardiak J
    Klin Onkol; 2014; 27(6):429-33. PubMed ID: 25493582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
    Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
    Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
    García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
    Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).
    Kim KH; Hong SJ; Han KS
    BMC Cancer; 2015 Oct; 15():812. PubMed ID: 26506914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
    Urakami S; Fujii Y; Yamamoto S; Yuasa T; Kitsukawa S; Sakura M; Yano A; Saito K; Masuda H; Yonese J; Fukui I
    Urol Oncol; 2014 Jan; 32(1):35.e1-7. PubMed ID: 23562233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
    Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Park JH; Lee JL
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future perspectives in advanced bladder cancer: is there a new standard?
    von der Maase H
    Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
    Takeyama Y; Kato M; Nishihara C; Yamasaki T; Iguchi T; Tamada S; Kuratsukuri K; Nakatani T
    Int J Clin Oncol; 2018 Oct; 23(5):944-950. PubMed ID: 29785621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Alva A; Daignault S; Smith DC; Hussain M
    Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
    Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
    Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R
    J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
    Terakawa T; Miyake H; Yokoyama N; Miyazaki A; Tanaka H; Inoue T; Fujisawa M
    Urol Int; 2014; 92(2):180-5. PubMed ID: 24246751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
    Albers P; Park SI; Niegisch G; Fechner G; Steiner U; Lehmann J; Heimbach D; Heidenreich A; Fimmers R; Siener R;
    Ann Oncol; 2011 Feb; 22(2):288-94. PubMed ID: 20682548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.
    Matsumoto K; Mochizuki K; Hirayama T; Ikeda M; Nishi M; Tabata K; Okazaki M; Fujita T; Taoka Y; Iwamura M
    Asian Pac J Cancer Prev; 2015; 16(6):2483-7. PubMed ID: 25824784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.